Publications by authors named "Keith A Pappa"

Claim this Profile
E
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Keith A Pappa

Clin Infect Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Pedro Cahn, Juan Sierra Madero, José R Arribas, Andrea Antinori, Roberto Ortiz, Keith A Pappa

AIDS· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Jean van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Keith A Pappa

Clin Infect Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, Jihad Slim, Vicenç Falcó, Keith A Pappa

J Acquir Immune Defic Syndr· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Pedro Cahn, Juan Sierra Madero, José R Arribas, Andrea Antinori, Roberto Ortiz, Keith A Pappa

J Acquir Immune Defic Syndr· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.
M Keith Rawlings, Jennifer Klein, Edna P Toubes Klingler, Ejeanée Queen, Lauren Rogers, Keith A Pappa

HIV AIDS (Auckl)· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Eric S Daar, Camlin Tierney, Margaret A Fischl, Paul E Sax, Katie Mollan, Keith A Pappa

Ann Intern Med· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Lisa L Ross, Winkler G Weinberg, Edwin DeJesus, Margaret A Fischl, Joseph H Horton, Keith A Pappa

AIDS Res Hum Retroviruses· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies.
Belinda Ha, Qiming M Liao, Lynn P Dix, Keith A Pappa

HIV Clin Trials· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Charles B Hicks, Edwin DeJesus, Louis M Sloan, Michael G Sension, David A Wohl, Keith A Pappa

AIDS Res Hum Retroviruses· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Ricky Hsu, Ernest R Lanier, Elizabeth G Rouse, Katrina L Oie, Keith A Pappa

Antivir Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
Kimberly Y Smith, Winkler G Weinberg, Edwin DeJesus, Margaret A Fischl, Qiming Liao, Keith A Pappa

AIDS Res Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Peter J Ruane, Andrew D Luber, Mary Beth Wire, Yu Lou, Mark J Shelton, Keith A Pappa

Antimicrob Agents Chemother· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.
Matthew Bidwell Goetz, Monique R Ferguson, Xueliang Han, Greg McMillan, Marty St Clair, Keith A Pappa

J Acquir Immune Defic Syndr· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Jeffrey P Nadler, Joseph C Gathe, Richard B Pollard, Gary J Richmond, Qiming Liao, Keith A Pappa

BMC Infect Dis· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis